Fremanezumab Among Latest EU Drug Hopefuls While Patients Speak Up On Pacritinib

Marketing applications for Teva’s migraine prevention CGRP inhibitor, fremanezumab, and CTI BioPharma’s myelofibrosis treatment, pacritinib, are among a number of submissions scheduled for discussion this week by the European Medicines Agency’s drug evaluation committee, the CHMP.